// App-Quantinova.ai

498 : CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

Researchers

Presenter

  • Robert J. Motzer

Principal Investigators

  • David F. McDermott

  • Saby George

  • Hans J. Hammers

  • Sandhya Srinivas

  • Scott S. Tykodi

  • Jeffrey Alan Sosman

  • Giuseppe Procopio

  • Elizabeth R. Plimack

  • Daniel E. Castellano

  • Howard Gurney

  • Frede Donskov

  • Petri Bono

  • John Wagstaff

  • Thomas Christoph Gauler

  • Takeshi Ueda

  • Huanyu Zhao

  • Ian M Waxman

  • Bernard Escudier

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Roswell Park Cancer Institute, Buffalo, NY

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Stanford Univeresity Medical Center, Stanford, CA

  • University of Washington Seattle Cancer Care Alliance, Seattle, WA

  • Vanderbilt University Medical Center, Nashville, TN

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Fox Chase Cancer Center, Philadelphia, PA

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Westmead Hospital, Westmead, Australia

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Helsinki University Central Hospital Cancer Center, Helsinki, Finland

  • South West Wales Cancer Institute, Swansea, United Kingdom

  • Department of Surgery, University Hospital Essen, Essen, Germany

  • Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Institut Gustave-Roussy, Villejuif, France

Locations

  • United States

  • Italy

  • Spain

  • Australia

  • Denmark

  • Finland

  • United Kingdom

  • Germany

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Everolimus

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01668784

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved